BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting

Rhea-AI Summary

BioVie (NASDAQ: BIVI) announced two abstracts on its lead candidate bezisterim (NE3107) were accepted for poster presentation at the 2026 American College of Psychiatrists annual meeting, Feb 18-22 in Bonita Springs, FL.

Both posters will be presented on February 18, 2026, covering bezisterim effects in Alzheimer’s disease and baseline characteristics from the Phase 2 Long COVID study (ADDRESS-LC).

Key Figures

SUNRISE-PD enrollment: 60 patients ADDRESS-LC duration: 16 weeks Long COVID prevalence: 400 million people +5 more

8 metrics

SUNRISE-PD enrollment 60 patients Phase 2 trial in early Parkinson’s disease

ADDRESS-LC duration 16 weeks Double-blind randomized placebo-controlled Long COVID trial

Long COVID prevalence 400 million people Estimated global Long COVID population

US Long COVID 18 million people Estimated Long COVID population in the United States

CEO option grant 665,300 options Stock options granted Jan 5, 2026 to Cuong V Do

Option exercise price $1.31 per share Exercise price for multiple insider stock option grants

Current share price $1.15 Pre-news trading price vs 52-week range

52-week range $1.06–$19.093 52-week low and high for BIVI

Market Reality Check

Price: $1.11 Vol: Volume 74,529 is 0.73x th...

normal vol

$1.11 Last Close

Volume Volume 74,529 is 0.73x the 20-day average of 101,693, showing muted trading interest pre-announcement. normal

Technical Shares at $1.15 are trading below the 200-day MA of $4.31 and far under the $19.093 52-week high.

Peers on Argus

BIVI fell 3.36% with several biotech peers also down: IMNN -2.01%, MTVA -6.21%, ...

BIVI fell 3.36% with several biotech peers also down: IMNN -2.01%, MTVA -6.21%, NERV -0.16%, NXTC -0.08%, while BCTX was flat. This points to a broader weak biotech tape alongside company-specific news.

Historical Context

4 past events · Latest: Jan 08 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Phase 2 enrollment	Positive	-3.7%	Completed enrollment of 60 patients in SUNRISE-PD Phase 2 Parkinson’s trial.
Nov 19	Investor webinar	Positive	-4.2%	Announced December 9 investor webinar to discuss bezisterim and BIV201 programs.
Sep 26	Investor webinar	Positive	+3.3%	Planned October 8 webinar updating progress on bezisterim and BIV201 pipelines.
Aug 13	Clinical trial design	Positive	-2.4%	Presented DoD-funded ADDRESS-LC Phase 2 Long COVID trial design at conference.

Pattern Detected

Recent positive clinical and investor-relations news has often been met with negative price reactions, suggesting a pattern of selling into good news, with only one notable positive reaction among the last four events.

Recent Company History

Over the last six months, BioVie has focused on advancing bezisterim (NE3107) across neurodegenerative and Long COVID indications. On Aug 13, 2025, it highlighted the fully DoD‑funded ADDRESS‑LC Phase 2 Long COVID trial with a 16-week randomized design. Subsequent investor webinars in September and November 2025 emphasized bezisterim and BIV201. On Jan 8, 2026, BioVie completed enrollment of 60 early Parkinson’s patients in the Phase 2 SUNRISE‑PD trial. Today’s abstract acceptances fit this ongoing clinical‑data visibility trend.

Market Pulse Summary

This announcement adds scientific visibility for bezisterim through poster presentations on Alzheime...

Analysis

This announcement adds scientific visibility for bezisterim through poster presentations on Alzheimer’s disease and Long COVID at the 2026 American College of Psychiatrists meeting. It follows recent milestones like Phase 2 SUNRISE‑PD enrollment of 60 patients and the DoD‑funded ADDRESS‑LC trial. Investors may focus on upcoming topline data timing, the robustness of clinical endpoints, and how these findings integrate with prior safety and efficacy results across indications.

Key Terms

phase 2, long covid, double-blind, randomized, +4 more

8 terms

phase 2 medical

"Phase 2 Study of Bezisterim (NE3107) in Long COVID (ADDRESS-LC)"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

long covid medical

"Bezisterim (NE3107), in the treatment of Alzheimer’s Disease and Long COVID"

A condition where symptoms from a viral infection persist or recur for weeks or months after the initial illness has cleared, often affecting energy, breathing, cognition or other body systems. It matters to investors because prolonged illness can change workforce availability, raise healthcare and insurance costs, shift demand for medical treatments and services, and influence regulatory and policy decisions—think of it as a lingering drag on productivity and expenses that can alter company performance.

double-blind medical

"16-week, double-blind, randomized, placebo-controlled design"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

randomized medical

"16-week, double-blind, randomized, placebo-controlled design"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

placebo-controlled medical

"16-week, double-blind, randomized, placebo-controlled design"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

stock options financial

"received a grant of 132,000 stock options on January 5, 2026"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

form s-8 regulatory

"has filed a Form S-8 registration statement for its 2019 Omnibus"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

equity incentive plan financial

"2019 Omnibus Equity Incentive Plan, which has been amended"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AI-generated analysis. Not financial advice.

CARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of two abstracts from studies on its lead candidate bezisterim (NE3107), in the treatment of Alzheimer’s Disease and Long COVID at the 2026 American College of Psychiatrists (ACP) annual meeting, to be held February 18-22, in Bonita Springs, FL.

The two abstracts have been accepted for presentation as posters during a session to be held on February 18, 2026. Details of the abstracts are as follows:

Abstract Title: Bezisterim-Associated Anti-inflammatory Epigenetic Modulation of Age Acceleration and Cognition in Alzheimer’s Disease

Authors: Joseph M. Palumbo¹; Christopher L. Reading¹; Jiayan Yan¹, Clarence Ahlem¹; Penelope Markham¹; Stephen O’Quinn¹; Varun B. Dwaraka²

Abstract Title: Baseline Characteristics of Currently Enrolled Participants in Phase 2 Study of Bezisterim (NE3107) in Long COVID (ADDRESS-LC)

Authors: Joseph M. Palumbo1*; Penelope Markham¹; Michael Peluso³; Igor J. Koralnik⁴; Sherry Hsiang-Yi Chou⁴; Lisa McCorkell⁵; Chantal Petit⁶; Stephen O’Quinn⁷; Chris Reading¹; Clarence Ahlem¹; Jiayan Yan¹

Affilations: ¹BioVie Inc., ²TruDiagnostic, Inc., ³University of California, San Francisco; ⁴Feinberg School of Medicine, Northwestern University; ⁵Patient-Led Research Collaborative, Oakland, California; ⁶Biotechnant Solutions LLC; ⁷Perissos Inc.

About Bezisterim         

Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNF-α), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease, Long COVID, and Alzheimer’s disease.

In Parkinson’s disease, BioVie has already completed a Phase 2 study that showed patients with moderate- to severe Parkinson’s taking bezisterim with levodopa had better motor control and fewer morning symptoms compared to those taking levodopa alone. Few drug-related side effects were observed. The current SUNRISE-PD just completed enrolling 60 patients to evaluate whether bezisterim alone can help improve motor and non-motor symptoms for Parkinson’s patients who have not been treated with carbidopa/levodopa. Topline results are expected in mid‑2026.

For Long COVID, the ADDRESS-LC trial is enrolling about 200 patient to evaluate if bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long Covid, which are believed to be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate). Topline data is expected mid-2026.

In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with Alzheimer’s.

About BioVie Inc.         
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

For Investor Relations Inquiries:	For Media Inquiries:
Contact: Chuck Padala Managing Director, LifeSci Advisors, LLC chuck@lifesciadvisors.com	Contact: Melyssa Weible Managing Partner, Elixir Health Public Relations  mweible@elixirhealthpr.com

FAQ

What did BioVie (BIVI) announce about bezisterim abstracts for the ACP 2026 meeting?

BioVie announced two bezisterim (NE3107) abstracts were accepted for poster presentation. According to BioVie, both posters will be presented on February 18, 2026 at the American College of Psychiatrists annual meeting in Bonita Springs, FL.

Which bezisterim topics will BioVie (BIVI) present at ACP on February 18, 2026?

BioVie will present two posters: one on anti-inflammatory epigenetic modulation in Alzheimer’s, and one on baseline characteristics in the Phase 2 Long COVID study. According to BioVie, both abstracts detail clinical and biomarker-related findings for NE3107.

Is the Long COVID study (ADDRESS-LC) for bezisterim mentioned by BioVie (BIVI) a Phase 2 trial?

Yes, the announcement references the Phase 2 study called ADDRESS-LC for bezisterim. According to BioVie, the accepted abstract reports baseline characteristics of currently enrolled participants in that Phase 2 study.

When and where will BioVie (BIVI) present its bezisterim posters at ACP 2026?

The posters are scheduled for February 18, 2026 at the American College of Psychiatrists annual meeting in Bonita Springs, Florida. According to BioVie, both abstracts were accepted for poster presentation during that session.

Who are some authors and affiliations on the accepted BioVie (BIVI) bezisterim abstracts?

Authors include Joseph M. Palumbo, Penelope Markham and collaborators from BioVie and multiple institutions. According to BioVie, affiliations listed include TruDiagnostic, UCSF, Northwestern Feinberg, Patient-Led Research Collaborative and Biotechnant Solutions.